Share on StockTwits

Stock Analysts’ ratings reiterations for Wednesday, August 13th:

Applied Optoelectronics (NASDAQ:AAOI) had its strong-buy rating reiterated by analysts at Raymond James. They currently have a $28.00 price target on the stock, up from their previous price target of $26.00.

Acorn Energy (NASDAQ:ACFN) had its buy rating reaffirmed by analysts at Maxim Group. Maxim Group currently has a $4.00 target price on the stock, down from their previous target price of $5.00.

Alliance Data Systems (NYSE:ADS) had its neutral rating reaffirmed by analysts at JPMorgan Chase & Co.. The firm currently has a $283.00 price target on the stock, up from their previous price target of $277.00.

AMETEK (NYSE:AME) had its neutral rating reissued by analysts at Zacks. Zacks currently has a $54.00 target price on the stock. Zacks’ analyst wrote, “AMETEK reported better-than-expected second quarter results with both the top and bottom lines beating the Zacks Consensus Estimate. Guidance was also in line with expectations. The company excels in making strategic acquisitions, driving operational efficiencies on an ongoing basis, introducing new products and taking its core competencies to the global marketplace, all of which play an important role in driving its growth. A word of caution may be in order however, considering the weakness in its balance sheet and problems like integration issues and an overly high goodwill associated with an extremely aggressive acquisition strategy. We are therefore initiating coverage with a Neutral recommendation on AMETEK shares.”

Alpha and Omega Semiconductor (NASDAQ:AOSL) had its buy rating reaffirmed by analysts at Stifel Nicolaus. They currently have a $10.00 target price on the stock, up from their previous target price of $9.00.

Array BioPharma (NASDAQ:ARRY) had its outperform rating reaffirmed by analysts at Leerink Swann. Leerink Swann currently has a $6.00 price target on the stock, down from their previous price target of $8.00.

Aircastle Limited (NYSE:AYR) had its neutral rating reissued by analysts at JPMorgan Chase & Co.. They currently have a $20.50 price target on the stock, up from their previous price target of $19.50.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) had its outperform rating reissued by analysts at Zacks. The firm currently has a $0.50 price target on the stock. Zacks’ analyst wrote, “On August 12, 2014, Brainstorm Cell Therapeutics, Inc. announced results for the second quarter of 2014. The company recorded no revenues and had a net loss of approximately $2.0 million, or $0.01 per share. During the quarter, Brainstorm completed a $10.5 million private placement to strengthen the balance sheet and provide the necessary working capital for pre-clinical and clinical studies. BrainStorm has recently initiated a randomized, double-blind, placebo controlled, Phase 2 clinical trial in ALS in the U.S., with results expected in mid to late 2015. Additional upcoming catalysts include uplisting to a major exchange and advancement of an additional preclinical program into human clinical testing. “

Black Diamond Group (TSE:BDI) had its outperform rating reaffirmed by analysts at Scotiabank. The firm currently has a C$41.00 target price on the stock.

Broadridge Financial Solutions (NYSE:BR) had its neutral rating reaffirmed by analysts at JPMorgan Chase & Co.. They currently have a $45.00 price target on the stock, up from their previous price target of $41.00.

Boston Scientific (NYSE:BSX) had its neutral rating reissued by analysts at Zacks. They currently have a $13.00 target price on the stock.

Cardtronics (NASDAQ:CATM) had its overweight rating reissued by analysts at JPMorgan Chase & Co.. They currently have a $51.00 price target on the stock, up from their previous price target of $45.00.

CF Industries Holdings (NYSE:CF) had its neutral rating reaffirmed by analysts at Zacks. Zacks currently has a $260.00 price target on the stock.

Cree (NASDAQ:CREE) had its neutral rating reiterated by analysts at Susquehanna. They currently have a $42.00 target price on the stock, down from their previous target price of $50.00.

Cree (NASDAQ:CREE) had its overweight rating reaffirmed by analysts at JPMorgan Chase & Co.. JPMorgan Chase & Co. currently has a $56.00 price target on the stock, down from their previous price target of $62.00.

Convergys Corp (NYSE:CVG) had its neutral rating reaffirmed by analysts at Macquarie. Macquarie currently has a $23.00 price target on the stock, down from their previous price target of $25.00.

DARA BioSciences (NASDAQ:DARA) had its neutral rating reissued by analysts at Zacks. The firm currently has a $1.75 price target on the stock. Zacks’ analyst wrote, ” We are pleased with the DARA Bio second quarter financial results. Revenues exceeded Street consensus for the first time – signs that expectations going forward are too low and that the business is actually preforming well after over a year of revamping and restructuring. For 2014, we estimate revenues will be around $1.8 million. This is still a rather low number, but with growth of 432% in the second quarter alone we think the trajectory is clearly heading in the right direction and DARA can go from “expensive” on a Price-to-Sales ratio to “cheap” rather quickly. For example, for 2015 we project revenues of $4.75 million. With an industry average 5x P/S ratio and $15.9 million in cash, DARA Bio stock is looking fairly-valued at today’s price based solely on the commercial operations.”

Denison Mines Corp. (TSE:DML) had its market perform rating reissued by analysts at BMO Capital Markets.

Energy Transfer Partners (NYSE:ETP) had its neutral rating reaffirmed by analysts at Zacks. Zacks currently has a $60.00 price target on the stock. Zacks’ analyst wrote, “We are maintaining our Neutral recommendation on Energy Transfer Partners, reflecting a balanced risk/reward profile. ETP remains a premier MLP with strategically-positioned assets that serve major North American natural gas-producing basins. Moreover, we appreciate ETP’s recent decision to acquire Susser Holdings Corp, which will significantly expand its existing network of gas stations. However, we are concerned about the persistent increase in the partnership’s operating expenses, which has often led to negative earnings surprises. Additionally, in comparison to other MLP subgroups, Energy Transfer Partners is more sensitive to commodity price volatility, which remains a major liability, in our view.”

Evotec AG (NASDAQ:EVTC) had its overweight rating reaffirmed by analysts at JPMorgan Chase & Co.. JPMorgan Chase & Co. currently has a $31.00 target price on the stock, up from their previous target price of $27.00.

Phoenix New Media (NASDAQ:FENG) had its outperform rating reiterated by analysts at Macquarie. The firm currently has a $16.00 price target on the stock, down from their previous price target of $17.00.

Fidelity National Information Services (NYSE:FIS) had its neutral rating reaffirmed by analysts at JPMorgan Chase & Co.. JPMorgan Chase & Co. currently has a $63.00 price target on the stock, up from their previous price target of $57.00.

Fiserv (NASDAQ:FISV) had its neutral rating reiterated by analysts at JPMorgan Chase & Co.. The firm currently has a $67.00 price target on the stock, up from their previous price target of $60.00.

Global Payments (NYSE:GPN) had its neutral rating reiterated by analysts at JPMorgan Chase & Co.. The firm currently has a $77.00 target price on the stock, up from their previous target price of $74.00.

Home Inns & Hotels Management Inc. (NASDAQ:HMIN) had its overweight rating reiterated by analysts at JPMorgan Chase & Co.. They currently have a $43.00 price target on the stock, down from their previous price target of $46.00.

Heartland Payment Systems (NYSE:HPY) had its neutral rating reiterated by analysts at JPMorgan Chase & Co.. The firm currently has a $50.00 price target on the stock, up from their previous price target of $46.00.

Cellular Dynamics International (NASDAQ:ICEL) had its outperform rating reaffirmed by analysts at Leerink Swann. The firm currently has a $14.00 price target on the stock, down from their previous price target of $17.00.

ITI (NASDAQ:ITCI) had its outperform rating reaffirmed by analysts at Leerink Swann. The firm currently has a $35.00 price target on the stock, up from their previous price target of $34.00.

JDS Uniphase Corp (NASDAQ:JDSU) had its neutral rating reaffirmed by analysts at JPMorgan Chase & Co.. JPMorgan Chase & Co. currently has a $11.00 price target on the stock, down from their previous price target of $12.50.

51job (NASDAQ:JOBS) had its neutral rating reiterated by analysts at Macquarie. Macquarie currently has a $38.00 price target on the stock, down from their previous price target of $84.00.

Kate Spade & Co (NASDAQ:KATE) had its buy rating reissued by analysts at Nomura. The firm currently has a $38.00 target price on the stock, down from their previous target price of $43.00.

Klondex Mines (TSE:KDX) had its buy rating reiterated by analysts at M Partners. The firm currently has a C$3.50 price target on the stock.

CarMax (NYSE:KMX) had its neutral rating reissued by analysts at Zacks. They currently have a $52.00 price target on the stock. Zacks’ analyst wrote, “CarMax posted an 18.8% increase in earnings per share to $0.76 in the first quarter of fiscal 2015, surpassing the Zacks Consensus Estimate of $0.66. Net sales and operating revenues rose 13.3% to $3.75 billion, beating the Zacks Consensus Estimate of $3.57 billion. The year-over-year improvement in revenues was mainly attributable to increased used vehicle, new vehicle and wholesale vehicle sales. Over the long haul, CarMax’s focus on the used-vehicle market and its aggressive store expansion strategy should help it outperform peers. However, we are concerned about intense competition in the used-car market and the high cash outflow of the company. As a result, we have maintained our Neutral recommendation.”

Michael Kors Holdings (NASDAQ:KORS) had its buy rating reissued by analysts at Deutsche Bank.

LGI Homes (NASDAQ:LGIH) had its overweight rating reaffirmed by analysts at JPMorgan Chase & Co.. The firm currently has a $21.00 target price on the stock, up from their previous target price of $20.00.

Monster Beverage Corp (NASDAQ:MNST) had its neutral rating reiterated by analysts at Zacks. They currently have a $74.00 price target on the stock. Zacks’ analyst wrote, “Monster Beverage’s second-quarter 2014 adjusted earnings of $0.81 per share surpassed the Zacks Consensus Estimate by 6.6% and the year ago mark by 31.5% on the back of solid margins, better cost leverage, and a lower tax rate. Net sales fell shy of the consensus mark by 1.5%, due to softer growth rates in the Energy category in the U.S and international markets. Revenues continued to be eroded by cannibalization of sales of existing brands by new products. However, revenue rose 8.9% year over year on the back of a robust increase in sales of new products in the U.S. Margins also benefitted due to a decrease in cost of goods sold and lower allowances. Monster Beverage continued to incur higher professional service cost related to litigations and regulatory issues. Taking all these factors into account, we prefer to remain on the sidelines. We maintain our Neutral recommendation on the stock.”

Mindray Medical International Ltd (NYSE:MR) had its neutral rating reaffirmed by analysts at Zacks. The firm currently has a $32.00 price target on the stock. Zacks’ analyst wrote, “Mindray Medical posted a 1.9% fall in 2014-second quarter adjusted earnings per share to $0.53, but inched past the Zacks Consensus Estimate by $0.01. Net revenues came in at $334.5 million, up 8.9% y/y, driven by strong international sales. Sluggish purchasing and marketing activities in the Chinese healthcare sector continue to have an unfavorable impact on the company’s domestic sales. The company now expects 2014 net revenues to grow at least 10% over 2013, lower than the earlier guidance of 15%. However, Mindray maintains a decent product pipeline and brings out several products each year. We maintain our Neutral recommendation on Mindray and set a target price of $32.00.”

Mitsubishi UFJ Financial (NYSE:MTU) had its neutral rating reaffirmed by analysts at Zacks. They currently have a $6.00 price target on the stock. Zacks’ analyst wrote, “Mitsubishi UFJ reported net income for first-quarter (ended Jun 30) of fiscal year ended Mar 31, 2015, down from the year-ago period, depicting higher G&A expenses. Yet, the company recorded an increase in gross profits and lower credit costs. Though we are apprehensive about the heightening competition, expanding expense base and volatility in the Japanese economy going forward, we expect Mitsubishi UFJ’s strong business model, diversified product mix and higher gross profits to boost its bottom line. “

Northern Property Reit (TSE:NPR.UN) had its sector perform rating reissued by analysts at Scotiabank. The firm currently has a C$31.50 target price on the stock.

VeriFone Systems (NYSE:PAY) had its overweight rating reiterated by analysts at JPMorgan Chase & Co.. JPMorgan Chase & Co. currently has a $41.00 price target on the stock, up from their previous price target of $39.00.

Paychex (NASDAQ:PAYX) had its underweight rating reiterated by analysts at JPMorgan Chase & Co.. The firm currently has a $43.00 target price on the stock, up from their previous target price of $40.00.

Patterson Companies (NASDAQ:PDCO) had its neutral rating reiterated by analysts at Zacks. Zacks currently has a $41.00 price target on the stock. Zacks’ analyst wrote, “Patterson posted fourth-quarter fiscal 2014 earnings per share of $0.60, down $0.02 from the year-ago quarter and $0.06 from the Zacks Consensus Estimate. Revenues grew 14.2% to $1,102.1 million, but lagged the Zacks Consensus Estimate of $1,123 million. The company expects EPS in the range of $2.20-$2.30 for fiscal 2015. Medical revenues continue to be soft due to weaknesses in international markets. Moreover, continued decline in operating margin concerns us. We remain cautious about intense competition, unfavorable currency fluctuations and an uncertain macro economy. As such, we reiterate our Neutral recommendation on Patterson with a price target of $41.00. “

Royal Caribbean Cruises (NYSE:RCL) had its neutral rating reaffirmed by analysts at Zacks. Zacks currently has a $64.00 price target on the stock. Zacks’ analyst wrote, “Royal Caribbean reported second-quarter 2014 results and improved its guidance for 2014, given a solid booking environment mainly in European and Asian sailings. Adjusted earnings of $0.66 per share beat the Zacks Consensus Estimate by 24.5% and increased substantially year over year. The significant upside reflects higher year-over-year revenues and a strong booking environment. Total revenue increased 5.2% year over year to $1.98 billion, due to higher passenger ticket revenues as well as increased onboard spending. However, it missed the consensus mark by 0.5%, due to higher cruise operating expenses. Going forward, the company is expected to deliver solid results on strong booking trends, profitability initiatives and efforts to counter volatility in fuel prices. However, higher operating costs owing to increased marketing and promotional spend remain a major threat to the company’s margin. We are therefore Neutral on the stock.”

Reinsurance Group of America (NYSE:RGA) had its neutral rating reissued by analysts at Zacks. They currently have a $84.00 target price on the stock. Zacks’ analyst wrote, “Reinsurance Group’s second-quarter operating income of $2.23 per share was significantly ahead of the Zacks Consensus Estimate of $2.06. In the year-ago quarter, the company had posted an operating loss of $0.99 per share. The quarter’s results were driven by strong international earnings, both from Europe, Middle East and Africa (EMEA) and the Asia Pacific regions along with continued momentum in Global Financial Solutions. The company holds a niche position in the U.S. and Canada reinsurance markets. Additionally, the company is growing its international operations to reap the benefits of diversification. Reinsurance Group is also poised to benefit from the changing life reinsurance pricing environment. Disciplined capital management and strong investment grade ratings also make us optimistic on the stock. Nonetheless, an underperforming Australia business, currency exchange volatility and evolving capital requirements are some near-term headwinds. We thus maintain our Neutral recommendation on the stock. “

Salix Pharmaceuticals (NASDAQ:SLXP) had its outperform rating reiterated by analysts at Zacks. Zacks currently has a $153.00 price target on the stock. Zacks’ analyst wrote, “Salix’s second quarter EPS of $1.44 was above the Zacks Consensus Estimate of $1.28. Revenues increased 62% with the Santarus acquisition boosting results. The acquisition has boosted the portfolio and strengthened the company’s position in the gastrointestinal market. Although, Salix maintained revenue guidance, the company has cut its earnings guidance due to a higher number of fully diluted shares. Salix is also progressing with its pipeline and could see some approvals as well as label expansions in the coming quarters. Moreover, the upcoming merger with Cosmo is an important step for Salix strategically as well as financially. The company will enjoy a tax efficient corporate structure. We believe Salix is poised for strong growth and Outperform recommendation. “

TriNet Group (NASDAQ:TNET) had its overweight rating reissued by analysts at JPMorgan Chase & Co.. They currently have a $34.00 target price on the stock, up from their previous target price of $29.00.

Time Warner (NYSE:TWX) had its neutral rating reissued by analysts at Zacks. Zacks currently has a $77.00 price target on the stock.

Union Pacific (NYSE:UNP) had its neutral rating reiterated by analysts at Zacks. Zacks currently has a $105.00 target price on the stock. Zacks’ analyst wrote, “We are maintaining our Neutral recommendation on Union Pacific on several grounds. We are encouraged by the expansion of the U.S. economy, which in turn will offer growth opportunities across various sectors. In the near term, we expect growth in shipment related to automotive, ethanol, housing and grains to drive revenues. Additionally, strength in the housing market along with the domestic highway conversion will also bolster the company’s prospects. We also appreciate Union Pacific’s focus on returning more wealth to shareholders via dividends and share buybacks. However, 2014 being a legacy light year could affect the company’s pricing. Further, fierce competition, rise in expenditure, a moderating international intermodal and regulatory issues somewhat dampen our optimism regarding the company.”

Usa Compression Partners (NASDAQ:USAC) had its outperform rating reaffirmed by analysts at Raymond James. The firm currently has a $33.00 target price on the stock, down from their previous target price of $34.00.

Visa (NYSE:V) had its overweight rating reissued by analysts at JPMorgan Chase & Co.. The firm currently has a $243.00 price target on the stock, up from their previous price target of $237.00.

The Valspar (NYSE:VAL) had its neutral rating reaffirmed by analysts at JPMorgan Chase & Co.. The firm currently has a $83.00 target price on the stock, up from their previous target price of $76.00.

Vantiv (NYSE:VNTV) had its overweight rating reiterated by analysts at JPMorgan Chase & Co.. JPMorgan Chase & Co. currently has a $42.00 target price on the stock, up from their previous target price of $37.00.

Volcano (NASDAQ:VOLC) had its market perform rating reissued by analysts at Leerink Swann. Leerink Swann currently has a $15.00 price target on the stock, down from their previous price target of $18.00.

WEX (NYSE:WEX) had its neutral rating reiterated by analysts at JPMorgan Chase & Co.. The firm currently has a $118.00 target price on the stock, up from their previous target price of $95.00.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.